Clinical trials located in

Newcastle upon Tyne

Newcastle upon Tyne city is located in United Kingdom. Currently, 20 clinical trials are being conducted in this city.

Newcastle upon Tyne, often simply called Newcastle, is a vibrant city in the northeast of England, known for its rich history, iconic Tyne Bridge, and strong cultural heritage. It was once a major shipbuilding and manufacturing hub. The city is home to the Newcastle University, renowned for its research and academic excellence. The historic heart, Newcastle Castle, gives the city its name, showcasing its medieval roots. The Quayside along the River Tyne is famous for its modern art spaces, including the BALTIC Centre for Contemporary Art and the innovative Sage Gateshead music venue. Newcastle’s passionate football culture centers around St. James’ Park, the beloved stadium of Newcastle United FC.

  • CT-EU-00118701

    Study on SAGE-718 for improving cognitive function in Huntington’s disease

    This study focuses on Huntington’s Disease and aims to evaluate the effect of SAGE-718 on cognitive performance and functioning. Huntington’s Disease is a genetic disorder that affects the brain and leads to cognitive decline and motor dysfunction. The study will involve the drug SAGE-718 and a placebo. The primary goal is to understand how SAGE-718 impacts cognitive abilities in participants with Huntington’s Disease over 84 days. Participants will be randomly assigned to receive either the drug or a placebo daily, and their cognitive performance will be assessed using various tests.

    • SAGE-718
    • placebo
  • Study of ustekinumab and guselkumab in young patients with juvenile psoriatic arthritis

    This here clinical trial is aimin’ to study two different medicines, ustekinumab and guselkumab, for treatin’ a condition called juvenile psoriatic arthritis. This is a type of arthritis that affects young’uns and causes joint pain, swellin’, and stiffness.

    The study will have two groups, one group takin’ ustekinumab and the other takin’ guselkumab. These medicines work by targetin’ certain proteins in the body that cause inflammation, which is the root cause of the arthritis symptoms.

    The main goal of the study is to see how well these medicines work in reducin’ the symptoms of juvenile psoriatic arthritis, like joint pain and swellin’. The study will also look at how the body handles these medicines and if they cause any side effects.

    The study will last for about a year and a half, with regular check-ups and assessments to monitor the participants’ progress.

    • Ustekinumab
    • Guselkumab
  • Gene Therapy Trial for Limb-Girdle Muscular Dystrophy Type R9

    This here clinical trial is called the “GNT0006 Gene Therapy Trial in Patients With LGMDR9“. It’s a study to test the safety and effectiveness of a new gene therapy treatment for a rare muscle disease called LGMDR9, also known as limb-girdle muscular dystrophy type R9.

    The study has two main parts. In the first part, called Stage 1, a small group of patients will receive the gene therapy treatment at different dose levels to make sure it’s safe and to find the best dose. In the second part, called Stage 2, a larger group of 33 patients who can still walk will be split into two groups. One group will get the gene therapy treatment at the best dose found in Stage 1, and the other group will get a placebo, which is like a fake treatment. After one year, the groups will switch treatments.

    The main thing the researchers are looking at is how the gene therapy affects the patients’ lung function, measured by something called Forced Vital Capacity. They’ll be checking this at different time points up to one year after the treatment. The study will also look at whether the treatment is safe and how long the effects last, with patients being followed for up to 5 years after receiving the real gene therapy treatment.

    So in a nutshell, this is a clinical trial testing a new gene therapy for a rare muscle disease, with the main goal being to see if it can improve lung function and whether it’s safe for patients to take. The study will take several years to complete, but could lead to an important new treatment option for people with this condition.

  • Study of melanoma patients using cell therapy – ATL001

    This is a study to test a cell therapy called ATL001 in melanoma patients. ATL001 consists of immune cells taken from the patient that can recognize and attack cancer cells. The study consists of two parts:

    First, part of the cancer tissue will be removed to produce ATL001 specifically for the patient. The subject will then receive chemotherapy to temporarily suppress the immune system before being infused with ATL001 cells. This makes it easier for ATL001 cells to find and fight cancer cells.

    The main goal is to evaluate the safety of ATL001 and any side effects that may occur. The study will also test whether ATL001 can help shrink or control melanoma. The patient will be monitored closely for 24 months after receiving ATL001, and then followed for at least 5 years to detect any long-term effects.

    • Niwolumab
    • ATL001
  • Comparing ruxolitinib, hydroxycarbamide, and Interferon as first-line treatments for high-risk Polycythemia Vera

    The study, known as MITHRIDATE, investigates the effectiveness of the drug Ruxolitinib compared to either Hydroxycarbamide or Interferon Alpha for patients with high-risk Polycythemia Vera, a type of blood disorder. This Phase III clinical trial aims to determine which treatment is more effective in managing the disease without leading to additional health complications.

    Patients in the trial are assigned to receive either Ruxolitinib or the best available therapy, chosen from Hydroxycarbamide or Interferon Alpha, as decided by the overseeing doctors. The course of the study involves regular monitoring and assessments to evaluate the impact of these treatments on the disease’s progression and patients’ overall health and quality of life. The study is conducted in a controlled environment to ensure reliable results.

    • Interferon-Alpha
    • Hydroxycarbamide
    • Ruxolitinib
  • Study of the new oral drug LY3871801 for rheumatoid arthritis

    The aim of this study is to test a new drug called LY3871801 for people suffering from moderate to severe rheumatoid arthritis. The main goal is to see if this new drug can help reduce disease activity and improve symptoms better than a placebo. In the first part of the study, doctors will check how much the Disease Activity Score changes after 12 weeks of taking LY3871801 or a placebo. Then, in the second part, they will look at what percentage of patients experience significant improvement, defined as achieving an ACR50 response, which means reducing symptoms of rheumatoid arthritis by 50% or more. Both the real drug and the placebo will be taken by mouth.

    • placebo
    • LY3871801
  • ARTEMIS study: Protecting kidney health in heart surgery patients with Ravulizumab

    The ARTEMIS study aims to find a new way to protect people with chronic kidney disease (CKD) undergoing heart surgery requiring the use of a heart-lung machine, also known as cardiopulmonary bypass (CPB). The main aim of this study is to see if a single dose of a drug called ravulizumab given intravenously can reduce the risk of serious kidney problems after surgery, compared with a placebo. Kidney issues are grouped under serious adverse events, and investigators will monitor them for up to 90 days after surgery. The study is carefully controlled and participants will not know whether they are receiving ravulizumab or a placebo to ensure the results are unbiased. This is an important test for people with chronic kidney disease undergoing heart surgery because it may lead to better outcomes and a lower risk of kidney damage after surgery.

    • placebo
    • Ravulizumab
  • Study on the effectiveness and safety of BBP-418 for Limb Girdle Muscular Dystrophy 2I patients

    This clinical trial is focused on a new treatment option for individuals diagnosed with Limb Girdle Muscular Dystrophy 2I (LGMD2I). This study is designed to explore the efficacy and safety of a medication called BBP-418 (Ribitol), which is administered as an oral solution. The medication is in the form of granules that are mixed with water to create a drinkable solution.

    The aim is to include participants aged 12 to 60 years old, covering a wide range of individuals affected by LGMD2I. Throughout a 36-month period, the study will closely monitor changes in the muscle function and overall health of the participants to determine the effectiveness and safety of BBP-418 in treating LGMD2I.

    A key aspect being observed is the change from baseline in the North Star Assessment for Limb Girdle Muscular Dystrophy after 36 months of treatment. This will aid in understanding the impact of BBP-418 on muscle function. In addition, the frequency and severity of any treatment-emergent adverse events will be tracked to ensure the medication’s safety over the long term.

    This study is a randomized, placebo-controlled, double-blind study, meaning participants will be randomly assigned to receive either the BBP-418 treatment or a placebo, with neither the participants nor the study staff aware of which group they are in. This approach helps ensure the reliability of the study results.

    • BBP-418 (ribitol)
  • Study on the effectiveness of Givinostat in Non-Walking Duchenne Muscular Dystrophy Patients

    This clinical trial is focused on testing the effectiveness, safety, and how well patients can tolerate a medication called Givinostat for those who have Duchenne Muscular Dystrophy (DMD) and can no longer walk. The study is designed for male pediatric patients aged between 9 to less than 18 years. A total of 138 participants will be involved, and they will be divided into two groups. One group will receive Givinostat, and the other group will receive a placebo, which is a substance with no therapeutic effect, designed to mimic Givinostat. This division will be done randomly and both the patients and the doctors will not know who is receiving the actual medication and who is receiving the placebo, making this a double-blind study.

    The main goal of this study is to see if Givinostat can help reduce muscle decline in patients with DMD who cannot walk, by looking at changes in upper limb function after 18 months of treatment. The safety and tolerability of Givinostat in these patients will also be closely monitored.

    Participants will be involved in the study for about 20 to 21 months, which includes a 4-week screening period to confirm eligibility, 18 months of treatment, and a follow-up period. At the end of the treatment period, all participants, regardless of which group they were in, will have the option to join a long-term safety study where they will receive Givinostat.

    • Givinostat
  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    • Enzalutamide/Xtandi
    • Darolutamide/Nubequa
    • Abiraterone Acetate/Zytiga
    • Saruparib
  • Investigating efficacy and safety of new therapy in early-stage Parkinson’s disease

    This clinical trial aims to examine BIIB122, a new medication considered to potentially slow down the progression of early-stage Parkinson’s disease in patients aged between 30–80 years old. Participants will undergo treatment with either BIIB122 or a placebo equal in appearance but devoid of actual medicine. The trial’s routine includes a single daily medication intake for a timeframe between 48 and 144 weeks. To evaluate the medication’s efficacy, patients’ symptoms and their impact on everyday life will be observed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In addition to this, safety assessment of BIIB122 will be a main focus of the study. The trial treats this as a double-blind study, anonymizing whether a patient takes the BIIB122 drug or a placebo.

    • BIIB122
  • Study on Seladelpar in Patients with Primary Biliary Cholangitis (PBC)

    Patients with Primary Biliary Cholangitis (PBC) can participate in a clinical trial involving the drug Seladelpar, available in 5 mg and 10 mg capsule forms. The trial aims to evaluate the long-term safety and tolerability of this drug, also known by the code MBX-8025.

    Seladelpar is being tested on a group of approximately 500 patients to determine its long-term tolerability and effectiveness in individuals with PBC. The objective is also to assess the drug’s impact on patient-reported symptoms, such as itching (pruritus).

    The study includes individuals who have previously participated in PBC studies involving seladelpar. Participants will be monitored for 60 months to collect data on potential side effects and laboratory test results.

    The overall goal of the study is to improve the treatment of patients with Primary Biliary Cholangitis by thoroughly investigating the new drug in terms of its safety and efficacy.

    • Seladelpar
  • Testing tozorakimab’s effect on chronic lung disease symptoms

    This study is all about testing a new drug, Tozorakimab, for people who have COPD – a lung disease that makes it difficult to breathe—and have had a bad flare-up in the past year. The researchers will give some people the new drug and some people a placebo (a dummy treatment) and see which works best. The drug is delivered in a shot under the skin, and all the people in the study will also keep taking their usual COPD medicines. The main things the researchers will be looking at are whether the new drug can reduce the number of flare-ups, improve quality of life (measured using a questionnaire), reduce the need for rescue medication and if it changes the results of breathing tests.

    • Tozorakimab
  • Comparing a new treatment with standard care for advanced colorectal cancer

    This research study is for people suffering from a type of bowel cancer that has spread to other parts of the body, known as ‘metastatic colorectal cancer’. The purpose of the study is to compare a new combination of medications against the regular treatments that are already in use. Patients participating in the study will be placed into two groups: one group will receive the standard treatment, and the other group will try a new combination of drugs (tucatinib, trastuzumab, and 5-Fluorouracil, leucovorin,,oxaliplatin). This study will also help to understand the side effects, which are any unexpected symptoms or changes that can occur when taking these medications. Ultimately, the goal of this study is to help learn more about which treatment is more effective in delaying the progression of the disease and improving the patients’ quality of life.

    • levoleucovorin
    • leucovorin
    • Fluorouracil
    • Bevacizumab
    • Cetuximab
    • Tucatinib
    • Oxaliplatin
    • Trastuzumab
  • Examining new drug impact on nonalcoholic fatty liver disease

    This study is evaluating GSK4532990 in adults with advanced non-alcoholic steatohepatitis (NASH). This is a Phase 2b trial comparing GSK4532990 with placebo, focusing on liver fibrosis and inflammation relief. The study will include high-dose, low-dose and placebo groups and will include 246 participants. Primary outcomes are improvement in histologic fibrosis and resolution of NASH at 52 weeks. Secondary outcomes include changes in liver and fat markers.

    • GSK4532990- new potential medication for fatty liver disease
  • Research on medicine combination for B-cell Non-Hodgkin Lymphoma

    This study is about testing epcoritamab, a new drug for a type of blood cancer called B-cell Non-Hodgkin Lymphoma. The goal is to see if the drug is safe for people and can successfully fight the cancer. Doctors will combine this drug with other medicines that are typically used to treat this cancer. The combined treatment will vary for different groups of patients, depending on factors like their specific type of cancer or their overall health. Some patients will be given epcoritamab on its own, while others will receive it with other cancer medicines. The study has two parts. The first part is to find a safe dose of the drug. The second part is to determine how well this drug helps in treating the cancer. Side effects will be closely monitored during the study.

    • etoposide phosphate
    • oxaliplatin
    • Prednisone
    • Dexamethasone
    • Carboplatin
    • Epcoritamab
    • Ifosfamide
    • Cytarabine
    • Gemcitabine
    • Cyclophosphamide
    • Vincristine
    • Doxorubicin
    • Bendamustine
    • Lenalidomide
    • Rituximab
  • Testing the safety and effectiveness of a new drug on patients with Duchenne muscular dystrophy

    This study aims to test DYNE-251, a new medicine for people with a specific type of Duchenne muscular dystrophy (amenable to exon 51 skipping)- a muscle weakening disease. The goal is to evaluate if it’s safe, if people can tolerate it well, and if it helps produce a crucial muscle protein called dystrophin. Participants will be given DYNE-251 intravenous in the increasing doses in several stages. The study includes different phases, starting with a 24-week test period, followed by long-term observation. To measure the effects, the researchers will use a functional scale for motor abilities and a score for upper limb function.

    • DYNE-251- new potential medication for Duchenne muscular dystrophy
  • Iptacopan’s effect on adult patients with atypical hemolytic uremic syndrome

    This study is conducted to understand if a medicine called iptacopan (also known as LNP023) is safe and effective in treating a disease called Atypical Hemolytic Uremic Syndrome (aHUS) in adults who have never received a type of medication known as a complement inhibitor. Around 50 adults will be given 200 mg of this iptacopan pill twice a day. The doctors will measure how their illness responds by looking at blood tests, kidney health, how often they need to have their blood cleansed by a machine (dialysis), the progression of their kidney illness, and how they feel energetically and about their quality of life. Side effects of taking iptacopan will be recorded for a year.

    • Iptacopan
  • Exploring new cancer treatment for small cell lung cancer and neuroendocrine neoplasms

    The DAREON™-5 study is looking at how different amounts of a cancer drug called BI 764532 can help people with a specific type of lung cancer called small cell lung cancer, as well as other euroendocrine neoplasms. The goal is to find the right dose of BI 764532, which can be manageable for patients when taken by itself. BI 764532 is a special type of molecule that could potentially boost the body’s immune system to fight cancer. The individuals participating in the study will receive the drug through a vein and the treatment’s effectiveness will be monitored regularly until the end of the study.

    • BI 764532- new potential medication for small cell lung cancer and neuroendocrine carcinomas
  • Evaluating the efficacy of macitentan in the treatment of high pulmonary artery blood pressure

    This study is checking if a 75 mg dose of a medicine called Macitentan can do a better job for patients with a lung condition called Pulmonary Arterial Hypertension (PAH) compared to a 10 mg dose. The main goal is to see if the 75 mg dose can better delay the patient’s first major health event related to PAH. Major events include things like unplanned hospital stays related to PAH, or their PAH getting worse. The researchers will check if patients’ PAH gets worse by looking at things like their physical exercise ability and signs of heart failure. The study also looks at how patients’ symptoms change from day to day.

    • macitentan

See more clinical trials in other cities in United Kingdom:

.